Coexpression of p53 protein and MDR functional phenotype in leukemias: The predominant association in chronic myeloid leukemia

Cytometry Part B - Clinical Cytometry

Volumn 61, Issue 1, 2004, Pages 1-8

  Cavalcanti Jr , Geraldo Barroso ^a,b   Vasconcelos, Flavia Da Cunha ^a   De Faria, Giselle Pinto ^a   Scheiner, Marcos Antônio Maurício ^a   Dobbin, Jane De Almeida ^a   Klumb, Claudete Esteves ^a   Maia, Raquel C ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Flow cytometry; Multidrug resistance; p53 protein; Rhodamina 123

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53; RHODAMINE 123;

ACCELERATED PHASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; BIOASSAY; BLASTIC PHASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

BLAST CRISIS; BONE MARROW CELLS; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; FLUORESCENT DYES; GENES, MDR; HUMANS; K562 CELLS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID, CHRONIC; MUTATION; P-GLYCOPROTEIN; PHENOTYPE; RECURRENCE; RHODAMINE 123; SYNDROME; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4544242959     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.20013     Document Type: Article

References (52)

1. Stavrovskaya AA. Cellular mechanism of multidrug resistance of tumor cells. Biochemistry 2002;65:95-106.
2. List AF. Non P-glycoprotein drug export mechanisms of multi-drug resistance. Sem Hematol 1997;34:24-33.
3. Ross DD. Novel mechanisms of drug resistance in leukemias. Leukemia 2000;14:467-473.
4. Almquist KC, Loe DW, Hipfner DR, et al. Characterization of M (r) 190,000 multidrug resistance protein (MRP) in drug-selected transfected human tumor cell. Cancer Res 1995;55:102-110.
5. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance- associated protein, MRP. Eur J Cancer 1996;32:945-957.
6. Webb M, Brun M, Mcniven M, Le Couteur D, Crapt P. MDR-1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol 1998;102:710-717.
7. Dhooge C, Moerloose B, Laureys G, et al. Expression of the multidrug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: results of a long-term prospective study. Leuk Lymphoma 2002;43:309-314.
8. Pallis M, Turzannski J, Higashi Y, Russel N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002;43:1221-1228.
9. Poulain S, Lepelley P, Preudhome C, et al. Expression of the multidrug resistance-associated protein in myelodysplastic syndromes. Br J Haematol 2000;110:591-598.
10. Tulpule A, Sherrod A, Dhershika D, et al. Multidrug resistance (MDR-1) expression in aids-related lymphomas. Leuk Res 2002;26: 121-127.
11. Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 2002;98:323-330.
12. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255:459-462.
13. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997; 90:11037-11042.
14. Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin KV. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 1994;6:71-77.
15. Sullivan GF, Yang JM, Vassil A, et al. Regulation of expression of the multidrug resistance protein MRP by p53 in human prostate cancer cells. J Clin Invest 2000;105:1261-1267.
16. Wang Q, Beck WT. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 1998;58:5762-5769.
17. Bahr O, Wick W, Weller M. Modulation of MDR/MRP by wild-type and mutant p53. J Clin Invest 2001;107:643-646.
18. Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;:233-240.
19. Filippini G, Griffin S, Uhr M, et al. A novel flow cytometry method for the quantification of p53 gene expression. Cytometry 1998;31:180-186.
20. Kimura O, Sugamura K, Kijima T, et al. Flow cytometry examination of p53 protein in primary tumors and metastases to the liver and lymphonodes of colorectal cancer. Dis Colon Rectum 1996;39:1428-1433.
21. Dowell SP, Wilson POG, Derias NW, et al. Clinical utility of the immunocytochemistry detection of p53 protein in cytological specimens. Cancer Res 1994;54:2914-2918.
22. Klumb CE, Furtado DR, Resende LMM, Carrićo MK, et al. DNA sequence profile of TP53 gene mutation in childhood B-cell non-Hodgkin's lymphomas: prognostic implications. Eur J Haematol 2003; 71:81-90.
23. Koduru PRK, Raju K, Vadmal V, et al. Correlation between mutation in p53, p53 expression, cytogenetic, histologic type and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997;90:4078-4091.
24. Soussi T, Dehouche K, Béroud C. p53 website and analysis of p53 gene mutation in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 2000;15:105-113.
25. Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projections on the hematologic cell lineages. Blood 1994;84:2391-2411.
26. Kocialkowski S, Pezzella F, Morrison H, et al. Mutation in the p53 gene are not limited to classic 'hot spot' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol 1995;89:55-60.
27. Nieder C, Peterson S, Peterson C, et al. The challenger of p53 as predictive factor in Hodgkin's or non-Hodgkin's lymphoma. Ann Hematol 2001;80:2-8.
28. Harris NL, Jaffe ES, Diebold J, et al. The Word Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November, 1977. Hematol J 2000;1:53-66.
29. Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos L, Maia RC. Multi-drug resistance in tumor cells: characterization of the multi-drug resistant cell line K562-Lucena. Ann Acad Bras Cienc 2001;73:57-69.
30. Duthu A, Debuire B, Romano J, et al. p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene 1992;7:2161-2167.
31. Faharat N, van der Plas D, Praxedes M, Morila R, Matutes E, Catovsky D. Demonstration of cytoplasmatic and nuclear antigens in acute leukaemia using flow cytometry. J Clin Pathol 1994;47:843-849.
32. Silva KL, Vasconcelos FC, Marques-Santos LF, Kwee JK, Maia RC. CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype. Leuk Res 2003;27:243-251.
33. Twentyman PR, Rhodes T, Rayner SA. Comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 1994; 30:1360-1369.
34. Tafuri A, Gregori C, Petruci MP, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002;100:974-981.
35. Turpeinen M, Serpi R, Rahkolin M, Vähäkangas K. Comparison of anti p53 antibodies in immunoblotting. Biochem Biophys Res Commun 2002;293:850-856.
36. Preudhomme C, Lepelley P, Vachee A, et al. Relationship between p53 gene mutation and multidrug resistance (mdr1) gene expression in myelodisplastic syndromes. Leukemia 1997;7:1888-1890.
37. Sum RX, Coste J, Segara C, et al. MBR rearrangement and p-glycoprotein expression are not independent prognostic factor like p53 protein in malignant lymphoma. Clin Lab Haematol 1998;20:87-94.
38. Galimberti S, Marchetti A, Buttitta F, et al. Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res 1998;18:2973-2976.
39. Sullivan GF, Yang JM, Vassil A, et al. Regulation of expression of the multidrug resistance protein MRP by p53 in human prostate cancer cells. J Clin Invest 2000;105:1261-1267.
40. Preudhomme C, Fenaux P. The clinical significance of mutation of p53 tumour suppressor gene in haematological malignancies. Br J Haematol 1997;98:502-511.
41. Levine A. The p53 protein and it's interactions with the oncogene products of small DNA tumor viruses. Virology 1990;177:419-426.
42. Szebel L, Selivanova G, Magusson KP, et al. EBNA-5, an Epstein - Barr virus encoded nuclear antigen, binds to the retinoblastoma and p53 protein. Proc Natl Sci USA 1993;90:5455-5459.
43. Cordone I, Masi S, Mauro FR, et al. p53 expression in B-chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998;91:4342-4349.
44. Cuneo A, De Angeli C, Roberti MG, et al. Richter's syndrome in a case of atypical chronic lymphocytic leukemia with the t(11;14) (q13; q32): role for a p53 exon 7 gene mutation. Br J Haematol 1996;92: 375-381.
45. Slingerland JM, Minden MD, Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia. Blood 1991;77:1500-1507.
46. Tafuri A, Oregon C, Petrucci MT, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2003;100:974-981.
47. Dhooge C, Moerloose BD, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 1999;105:676-683.
48. Laupeze B, Amiot L, Drenou B, et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002;116:834-838.
49. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996; 74:63-68.
50. Park YB, Kin HS, Oh JH, Lee SH. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 2001;24:307-310.
51. O'Dwyer ME, Mauro MJ, Druker BJ. STI571 as a targeted therapy for CML. Cancer Invest 2003;21:429-438.
52. Mahon FX, Belloc F, Lagarde V, et al. MDR gene over-expression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373.